More than three years after it faced a huge setback with a study of Endobarrier, which is designed for patients diagnosed with type 2 diabetes and obesity, GI Dynamics Inc., of Boston, has received good news from the FDA. The agency has allowed a pivotal trial evaluating the safety and efficacy of Endobarrier in the U.S., pending institutional review board approval. Read More
